Locations
North America · Boston, MA, USA · West Street / River Street, Boston, MA, USA
industry
Biotechnology
Size
51-200 employees
Stage
Series C+
founded in
2018
Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Merck, and Pfizer. Dewpoint scientists work in Boston, Dresden, and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable.
Something looks off?